A Phase 2 interventional study of Tirzepatide and Placebo in Autosomal Dominant Polycystic Kidney and Obesity, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-06.
Sponsored by University of Colorado, Denver · Phase 2, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver — 1 open to participants now, 5 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · University of Colorado, Denver.
Among the 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 2, and was the 12th registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →1 of the 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver is open now, in 1 country.
By country, each count listing its studies:
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 126 is above the median of 51 across 138 interventional studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 61 across the 11 interventional studies, 22 across the 1 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
2 of the studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04907799University of Colorado, DenverDaily Caloric Restriction in ADPKD | 2027-06-30 |
| NCT06496542University of Colorado, DenverRenal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD | 2027-08-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques. Blood and urine samples will provide further insight into biological changes that may be linked to the benefits of the intervention, while ensuring careful monitoring of safety and tolerability.
Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited disorder that leads to kidney failure. The only approved treatment to decelerate kidney disease progression in patients with ADPKD is tolvaptan, but its usage is limited due to frequent side effects affecting adherence. Thus, alternative interventions that may slow ADPKD progression hold considerable clinical importance. In line with the general population, body-mass index and insulin resistance have been increasing in patients with ADPKD. The investigators have shown that visceral adiposity associates strongly with accelerated progression of early-stage ADPKD. Pilot study suggested that diet-induced weight loss may slow kidney growth (% in height-adjusted total kidney volume [htTKV] by magnetic resonance imaging), and the study team is currently evaluating the efficacy of daily caloric restriction-induced weight loss for slowing ADPKD progression in a phase IIa clinical trial. However, the long-term adherence to lifestyle interventions is challenging, making pharmacological interventions a compelling adjunct or alternative. Moreover, the study team recently demonstrated that adults with ADPKD and preserved kidney function exhibited insulin resistance (via the gold-standard hyperinsulinemic-euglycemic clamps) and impaired kidney oxidative metabolism (via 11C-acetate PET), which were strongly associated with htTKV. These novel data suggest that targeting improvements in insulin sensitivity and kidney oxidative metabolism, in addition to weight loss, may slow ADPKD progression. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) were recently FDA-approved for the treatment of obesity and show promise in substantially reducing adiposity and improving insulin sensitivity. Additionally, evidence indicates that GLP-1RAs may transform CKD management by reducing kidney events in patients with and without diabetes, via effects extending beyond glycemic modulation, and in part via attenuated kidney inflammation and oxidative stress. However, GLP-1RAs have not yet been evaluated as a novel therapy for slowing ADPKD progression in patients with overweight/obesity. Thus, the current study is a 12-month, phase II, randomized, placebo-controlled, double-blind clinical trial using a GLP-1RA in 126 adults with ADPKD and overweight or obesity to slow kidney growth (primary outcome). The trial will also evaluate changes in total body weight, adipose volume and function, insulin resistance, kidney oxidative metabolism, and inflammation, and carefully monitor safety and tolerability. As a novel therapeutic in ADPKD, GLP-1RAs could transform the treatment landscape for patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To minimize the risk of gastrointestinal adverse events, we will use a standard dose-escalation regimen for tirzepatide (placebo-matched), starting at 2.5 mg once weekly (OW) at randomization. After 4 weeks of treatment at 2.5 mg, the dose will be escalated to 5 mg OW, which will be maintained for another 4 weeks and then continued as the target dose for 10 months until the end of treatment. As with other nutrient stimulating hormone (NuSH) therapies, dose reductions and extensions of dose-escalation intervals will be permitted if participants experience unacceptable adverse events. The minimum tolerated dose required for continued study participation is 2.5 mg/week. All dose changes will be documented in the study records.
Drug: Tirzepatide
To minimize the risk of gastrointestinal adverse events, we will use a standard dose-escalation regimen for tirzepatide (placebo-matched), starting at 2.5 mg once weekly (OW) at randomization. After 4 weeks of treatment at 2.5 mg, the dose will be escalated to 5 mg OW, which will be maintained for another 4 weeks and then continued as the target dose for 10 months until the end of treatment. As with other nutrient stimulating hormone (NuSH) therapies, dose reductions and extensions of dose-escalation intervals will be permitted if participants experience unacceptable adverse events. The minimum tolerated dose required for continued study participation is 2.5 mg/week. All dose changes will be documented in the study records.
Other: Placebo
Titrated to dose of 5 mg once weekly subcutaneous
Also known as: Zepbound
Titrated to dose of 5 mg once weekly subcutaneous
Change in height-Adjusted Total kidney volume
To assess kidney growth,height-adjusted total kidney volume will be measured by magnetic resonance imaging at baseline and 12 months to determine annual percent change.
Time frame: Baseline, 12-months
Change in body weight
Change in body weight over the 12-month period will be measured using a calibrated digital scale.
Time frame: Baseline, 12-months
Change in abdominal adiposity
Abdominal adiposity (subcutaneous, visceral, and total) will be assessed by magnetic resonance imaging.
Time frame: Baseline, 12-months
Change in adiponectin (circulating)
Venous blood samples will be analyzed for this mechanistic biomarker
Time frame: Baseline, 6-months, 12-months
Change in leptin (circulating)
Venous blood samples will be analyzed for this mechanistic biomarker
Time frame: Baseline, 6-months, 12-months
Change in interleukin-6 (circulating)
Venous blood samples will be analyzed for this mechanistic biomarker
Time frame: Baseline, 6-months, 12-months
Change in tumor necrosis-factor-alpha (circulating)
Venous blood samples will be analyzed for this mechanistic biomarker
Time frame: Baseline, 6-months, 12-months
Change in high-sensitivity C-reactive protein (circulating)
Venous blood samples will be analyzed for this mechanistic biomarker
Time frame: Baseline, 6-months, 12-months
Change in 8-isoprostane (circulating)
Venous blood samples will be analyzed for this mechanistic biomarker
Time frame: Baseline, 6-months, 12-months
Change in copeptin (circulating)
Venous blood samples will be analyzed for this mechanistic biomarker
Time frame: Baseline, 6-months, 12-months
Change in HOMA-IR
The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) will use fasting glucose and insulin to calcuate insulin sensitivity
Time frame: Baseline, 6-months, 12-months
Change in HOMA-β
The Homeostatic Model Assessment of β-cell function (HOMA-β) will use fasting glucose and insulin to calcuate insulin secretion.
Time frame: Baseline, 6-months, 12-months
Change in 8-isoprostane (urinary)
Sport urine samples will be analyzed for this mechanistic biomarker
Time frame: Baseline, 6-months, 12-months
Change in copeptin (urinary)
Sport urine samples will be analyzed for this mechanistic biomarker
Time frame: Baseline, 6-months, 12-months
Change in renal oxygen consumption
Renal oxygen consumption will be assessed by a PET/CT scan using 11-C acetate in a sub-set of participants
Time frame: Baseline, 12-months
Change in gut microbiota
16S rRNA gene sequencing will be used for taxonomic characterization of the gut microbiota in a subset of participants.
Time frame: Baseline, 12-months
Change in renal blood flow
Phase contrast magentic resonance imaging will be used to measure change in renal blood flow
Time frame: Baseline, 12-months
Safety (adverse events)
Number of participants with treatment-related adverse events in each group as evaluated by the DSMB
Time frame: 12 months
Adherence
Compliance will be assessed by cross-checking the following sources and comparing these to the expected use: (1) drug accountability information; (2) counting returned trial product, visual inspection of pens; and (3) discussion with participants.
Time frame: 12 months
Tolerability (dropout due to adverse events)
Subject dropout due to treatment-emergent adverse events
Time frame: 12 months
Kidney Function Decline
Estimated glomerular filtration rate trajectories will be compared between the active and placebo group as an exploratory endpoint to inform a subsequent phase III trial.
Time frame: Baseline, 1 month, 3 months, 6-months, 12-months
Change in dietary energy Intake
Multiple pass 24-hr dietary recalls will be analyzed to evaluate self-reported energy intake
Time frame: Baseline, 1 month, 6-months, 12-months
Change in free-living physical activity
Estimated energy expenditure (METs) over a 7-day period will be quantified using the ActiGraph wGT3X-BT activity monitor
Time frame: Baseline, 12-months
Change in resting energy experniture
Resting energy expenditure will be assessed using indirect calorimetry.
Time frame: Baseline, 12 months
Change in percent body fat
Percent body fat will be assessed via DEXA scan in a sub-set of participants.
Time frame: Baseline, 12 months
Plan to share: Yes — Data obtained through this study may be provided to qualified researchers with academic interest in ADPKD. Data shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. data use agreement) are prerequisites to the sharing of data with the requesting party.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.
Access criteria: Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA).
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Jun 2029, 51 months after the start.
Of 17 phase 2 interventional studies under Polycystic Kidney, Autosomal Dominant, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 51 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide
Polycystic Kidney, Autosomal Dominant →
University of Colorado, Denver →